How adrenaline affects immune responses in cancer treatment with CAR T cells
Adrenergic modulation of cellular immune functions in CAR T cell-induced cytokine release syndrome
This study is looking at how adrenaline affects the immune responses in patients receiving CAR T cell therapy for cancer, especially focusing on a side effect called cytokine release syndrome, with the goal of finding ways to make this treatment safer and more effective for you.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hugo W. Moser Res Inst Kennedy Krieger NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11047305 on NIH RePORTER |
What this research studies
This research investigates the role of adrenaline in the immune responses triggered by CAR T cell therapy, a promising treatment for certain types of cancer. The study aims to understand how adrenaline influences the severity of cytokine release syndrome (CRS), a serious side effect of this therapy. By examining the mechanisms behind CRS, the researchers hope to develop better strategies to prevent and manage these adverse effects, ultimately improving the safety and effectiveness of CAR T cell treatments for patients. The approach includes both laboratory studies and patient observations to gather comprehensive data on adrenaline's impact.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing CAR T cell therapy for B-cell malignancies who may be at risk for cytokine release syndrome.
Not a fit: Patients who are not receiving CAR T cell therapy or those with other types of cancer unrelated to B-cell malignancies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer CAR T cell therapies with fewer severe side effects for cancer patients.
How similar studies have performed: Previous research has shown that understanding the immune response mechanisms can lead to improved management of adverse effects in cancer therapies, suggesting potential success for this approach.
Where this research is happening
Baltimore, United States
- Hugo W. Moser Res Inst Kennedy Krieger — Baltimore, United States (Active)
Researchers
- Principal investigator: Staedtke, Verena — Hugo W. Moser Res Inst Kennedy Krieger
- Study coordinator: Staedtke, Verena
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.